ReviewFrontiers in pharmacology2018

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.

Hasumati Rahalkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.